Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Multiplace Series
Hard-Shell Multiplace·2-18+ person
Pressure3 ATA
$150,000 - $400,000+
●●●○Moderate Evidence
Hyperbaric Therapy for Peripheral Artery Disease & Ischemic Wounds
Medicare covers HBOT for diabetic lower extremity wounds. Evidence shows meaningful amputation risk reduction — with angiogenesis as the key mechanism.
Hyperbaric oxygen therapy (HBOT) for Peripheral Artery Disease (PAD) has moderate clinical evidence. This is currently an off-label use and is not covered by insurance. The recommended protocol is 2.0–2.4 ATA ATA for 90–120 minutes per session per session over 20–40 sessions sessions.
Key Takeaways
- Medicare covers HBOT for diabetic lower extremity wounds (Wagner Grade III+) in accredited facilities
- Faglia et al. (2006) RCT: major amputation rate reduced from 33% to 8.6% with HBOT in diabetic foot disease
- Angiogenesis via VEGF upregulation creates structural new blood vessel formation — effects persist after treatment
- HBOT dissolves oxygen directly in plasma, delivering it to ischemic tissue even with compromised blood flow
- Requires 2.0–2.4 ATA — clinical-grade hard-shell chambers only; soft-shell chambers cannot treat this indication
What is Peripheral Artery Disease (PAD)?
Peripheral artery disease (PAD) is caused by atherosclerotic narrowing of arteries supplying the legs and feet, reducing blood flow and oxygen delivery to limb tissues. In severe cases — particularly in patients with diabetes — this leads to non-healing wounds, gangrene, and ultimately limb amputation. PAD affects an estimated 8–12 million Americans, with diabetic foot ulcers representing one of the leading causes of non-traumatic lower extremity amputation. HBOT intersects with PAD primarily through the diabetic wound healing indication. The FDA has approved HBOT for chronic, refractory diabetic wounds of the lower extremities, and Medicare reimburses HBOT for this indication in accredited facilities when specific clinical criteria are met (adequate tissue perfusion, wound not improving after 30 days of standard care). This represents one of the clearest coverage pathways in hyperbaric medicine. For PAD without active wounds — treating the vascular insufficiency itself — HBOT evidence is smaller and the indication is off-label. The angiogenesis mechanism (HBOT stimulates new blood vessel formation via VEGF) is biologically compelling, but clinical trial data for PAD as a primary indication is limited compared to the wound healing evidence. The distinction matters for both insurance coverage and treatment expectations.
How Hyperbaric Therapy Helps Peripheral Artery Disease (PAD)
In ischemic tissue, the core problem is insufficient oxygen delivery due to compromised blood vessels. HBOT addresses this through two distinct mechanisms. Acutely, it dramatically increases dissolved oxygen in plasma, bypassing hemoglobin and delivering oxygen directly to hypoxic tissues even where blood flow is severely compromised — providing a temporary but meaningful metabolic rescue. Over repeated sessions, HBOT triggers angiogenesis: upregulation of vascular endothelial growth factor (VEGF) and other angiogenic factors stimulates the formation of new blood vessels (neovascularization) in ischemic regions. This structural change can persist after treatment ends, improving baseline tissue perfusion. Additionally, HBOT has potent effects on wound healing — stimulating fibroblast activity, collagen synthesis, and antimicrobial defense — which directly addresses the non-healing wound component of diabetic PAD.
Recommended Protocol
Pressure
2.0–2.4 ATA
Sessions
20–40 sessions
Duration
90–120 minutes per session
What Does the Evidence Say?
●●●○Moderate Evidence
Faglia et al. (2006) conducted an RCT of 70 patients with diabetic foot wounds and PAD: HBOT significantly reduced the rate of major amputation (8.6% vs. 33.3% in controls). Huang et al. (2015) published a systematic review of 10 studies including 531 patients finding HBOT significantly improved wound healing and reduced amputation risk in diabetic foot disease. The Cochrane review of HBOT for chronic wounds (Kranke et al., 2015) found HBOT improved short-term healing of diabetic foot ulcers and reduced major amputations. Medicare coverage reflects the strength of this evidence — CMS reimburses HBOT for diabetic lower extremity wounds in accredited facilities when standard care has failed. For direct PAD treatment (without active wounds), evidence is thinner and coverage does not apply. Patients with critically ischemic limbs (very low ankle-brachial index) may not be good HBOT candidates, as insufficient flow can limit oxygen delivery even under pressure.
Off-Label Use
Peripheral Artery Disease (PAD) is not an FDA-approved indication for HBOT. Treatment is considered off-label and is typically not covered by insurance. Consult your physician before starting any HBOT protocol.
Recommended Chambers for Peripheral Artery Disease (PAD)
Based on the protocol requirements — minimum 2 ATA, Clinical Grade tier. Sorted by clinical credibility score.
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 34
Hard-Shell Monoplace·1-person
Pressure3 ATA
$50,000 - $90,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 36
Hard-Shell Monoplace·1-person
Pressure3 ATA
$55,000 - $95,000
Clinical GradeFDA Cleared
For Maximum Comfort
Perry Baromedical
Sigma 40
Hard-Shell Monoplace·1-person
Pressure3 ATA
$65,000 - $110,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 40-II
Hard-Shell Multiplace·2-person
Pressure3 ATA
$100,000 - $160,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma Elite
Hard-Shell Monoplace·1-person
Pressure3 ATA
$80,000 - $130,000
Frequently Asked Questions
Does Medicare cover HBOT for peripheral artery disease or diabetic foot wounds?
Medicare covers HBOT specifically for diabetic lower extremity wounds that meet clinical criteria: the wound must be Wagner Grade III or higher, not responding after 30 days of standard wound care, and the patient must have adequate tissue perfusion (transcutaneous oxygen pressure above a threshold). Coverage is for diabetic wound healing — not for PAD as a primary diagnosis. Treatment must occur in a Medicare-approved hyperbaric facility. Always verify coverage before starting treatment, as criteria are specific and prior authorization is typically required.
Can HBOT help avoid amputation in PAD patients?
For patients with diabetic foot wounds complicated by PAD, the evidence is encouraging. Faglia et al. (2006) found the major amputation rate dropped from 33% to 8.6% with HBOT added to standard care. Not every patient responds equally — those with some residual tissue perfusion tend to benefit more than those with critical ischemia and minimal blood flow. HBOT is most effective as part of a multidisciplinary limb salvage approach that includes vascular surgery evaluation, wound care, and infection management, not as a standalone treatment.
What is ankle-brachial index (ABI) and does it affect HBOT eligibility?
ABI compares blood pressure in the ankle to the arm — an ABI below 0.9 suggests PAD, and below 0.4 indicates severe ischemia. Transcutaneous oxygen pressure (TcPO2) measurements at the wound site are the more direct assessment for HBOT candidacy. Medicare requires a wound-site TcPO2 above 100 mmHg while breathing supplemental oxygen (or a specific threshold) to confirm that oxygen can reach the tissue under hyperbaric conditions. Patients with very severe ischemia (TcPO2 below 50 mmHg even with 100% O2) may not be candidates. A vascular surgery evaluation is recommended before starting HBOT for PAD-related wounds.
Do I need a hard-shell chamber for PAD treatment — will a home chamber work?
Yes — a hard-shell clinical-grade chamber is required. PAD treatment uses 2.0–2.4 ATA, which is beyond the capability of soft-shell home chambers (maximum 1.3 ATA). Additionally, PAD wounds require the highest achievable oxygen tension to overcome tissue ischemia — this demands both elevated pressure and 100% oxygen delivery, which only clinical-grade chambers provide. Home chambers are not appropriate for this indication. HBOT for diabetic wounds and PAD should be conducted at an accredited hyperbaric wound care center.
Related Conditions
Sources & References
- Faglia et al. (2006) — Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer, Diabetes Care
- Huang et al. (2015) — Hyperbaric oxygen therapy as adjunctive therapy for diabetic foot, Vascular
- Kranke et al. (2015) — Hyperbaric oxygen therapy for chronic wounds, Cochrane Database of Systematic Reviews
- CMS Medicare — National Coverage Determination for Hyperbaric Oxygen Therapy
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Ready to compare chambers?
Use our filterable directory to find chambers that match your protocol requirements.